How Is Psilocybin Metabolized In the Body?

Psilocybin itself is not the molecule that produces psychedelic effects. It is a prodrug, meaning your body must convert it into a different compound before it becomes active. That compound is psilocin, and the conversion happens quickly once psilocybin reaches your gut and liver. From there, psilocin follows a metabolic path that determines how fast effects come on, how long they last, and how the body eventually clears the substance.

The First Step Is Dephosphorylation

Psilocybin’s chemical structure includes a phosphate group attached to the indole ring. That phosphate group is the reason psilocybin is stable enough to survive in a mushroom and in your stomach, but it also makes the molecule unable to cross into the brain effectively on its own. The body removes that phosphate group through a process called dephosphorylation, carried out primarily by an enzyme called alkaline phosphatase.¹ This happens in the lining of the intestines and in the liver. The result is psilocin, which is structurally almost identical to psilocybin minus that phosphate group.

This conversion is fast. After you swallow psilocybin, alkaline phosphatase begins stripping the phosphate almost immediately, and psilocin starts appearing in the bloodstream within minutes. One way to think about it: psilocybin is the delivery vehicle, and psilocin is the payload. Nearly everything that happens next in terms of psychoactive effects and further metabolism involves psilocin, not psilocybin itself.

How Psilocin Moves Through the Bloodstream

Once psilocin enters circulation, it reaches peak blood levels roughly two hours after an oral dose, though the range across studies is about 1.8 to 4 hours depending on the dose, the formulation, and individual variation.² Peak concentrations scale with dose in a fairly predictable way. In one well-controlled study giving healthy volunteers 15, 25, or 30 mg of psilocybin, average peak psilocin levels were about 11, 17, and 21 nanograms per milliliter of blood, respectively.³ That linear relationship is reassuring from a clinical standpoint because it means doubling the dose roughly doubles the amount of active compound in the blood, rather than producing unpredictable spikes.

Psilocin also distributes widely through tissues. One systematic review reported a volume of distribution ranging from roughly 277 liters to over 1,000 liters, which is far larger than total body water and indicates that psilocin spreads extensively into tissues rather than staying confined to the blood.² That same review estimated oral bioavailability of psilocin at roughly 53%, meaning about half of the psilocybin you swallow ultimately makes it into the bloodstream as active psilocin. The rest is lost to incomplete absorption or first-pass metabolism in the gut wall and liver before it ever reaches general circulation.

How the Body Breaks Down Psilocin

Psilocin’s elimination half-life, the time it takes for blood levels to drop by half, ranges from about 1.5 to 4 hours across different studies. That study of 15, 25, and 30 mg doses found half-lives clustering around 1.4 to 1.8 hours,³ while another study using escalating doses reported a longer average of about 3 hours, with considerable variation between individuals.⁴ The discrepancy likely reflects differences in study design, analytical methods, and individual biology. Some participants in the latter study showed an extended elimination phase, which the authors attributed to a metabolite of psilocin (its glucuronide form) slowly breaking back down and releasing small amounts of psilocin into the blood.

The body eliminates psilocin through two main metabolic routes, which happen roughly in parallel.

Oxidative Breakdown by MAO-A

The first route is oxidation. An enzyme called monoamine oxidase A (MAO-A), the same enzyme responsible for breaking down serotonin and other neurotransmitters, attacks psilocin and converts it into an intermediate called 4-hydroxyindoleacetaldehyde (4-HIA).⁵ That aldehyde is unstable and gets quickly converted further into a terminal metabolite called 4-hydroxyindoleacetic acid (4-HIAA) by additional enzymes, including aldehyde oxidase and aldehyde dehydrogenases.⁵ This end product, 4-HIAA, is pharmacologically inactive and gets excreted in urine.

In vitro studies suggest that MAO-A transforms psilocin into these metabolites at relatively modest rates,⁶ which partly explains why psilocin hangs around long enough to produce effects lasting several hours. The MAO-A pathway also raises an interesting practical question about drug interactions, which we will come back to.

Glucuronidation

The second major route is a process called glucuronidation, where the body attaches a large sugar molecule (glucuronic acid) to psilocin’s hydroxyl group. This makes the molecule water-soluble and unable to cross into the brain, essentially deactivating it so the kidneys can excrete it. The enzymes responsible belong to a family called UDP-glucuronosyltransferases, or UGTs. When researchers tested 19 different human UGT enzymes against psilocin, UGT1A10 showed by far the highest activity, with UGTs 1A9, 1A8, 1A7, and 1A6 contributing at lower levels.⁷ UGT1A10 is expressed mainly in the gastrointestinal tract, which means a significant chunk of glucuronidation happens in the gut itself, even before psilocin reaches the liver.

The psilocin-glucuronide conjugate shows up abundantly in urine. Forensic researchers confirmed its presence by treating urine samples with an enzyme that cleaves glucuronide bonds: without that treatment, psilocin was undetectable in samples that clearly contained it once the glucuronide was broken apart.⁸ This finding has direct implications for drug testing, as we will see below.

Where Psilocin Acts Before It Is Cleared

Between absorption and elimination, psilocin exerts its psychedelic effects primarily by binding to serotonin receptors in the brain. Its main target is the serotonin 2A receptor (5-HT2A), but it also binds to related serotonin receptors with similar strength. In binding studies using both human and mouse brain tissue, psilocin showed comparable affinity for 5-HT2A, 5-HT2C, and 5-HT1A receptors.⁹ Molecular simulations suggest that psilocin binds to the same pocket on the 5-HT2A receptor as serotonin itself, with a strong preference for the main binding site over alternative docking locations on the receptor.¹⁰

This receptor binding is relevant to metabolism because the duration and intensity of subjective effects track closely with psilocin blood levels. As glucuronidation and MAO-A oxidation clear psilocin from the blood, receptor occupancy drops and the experience fades. The relatively short half-life of psilocin is the main reason a psilocybin experience typically winds down within four to six hours, even though trace amounts remain detectable longer.

Drug Testing and the Glucuronide Problem

Standard urine immunoassay panels used in workplace drug testing do not screen for psilocin or psilocybin. Specialized tests can detect psilocin, but there is a catch: most of the psilocin in urine exists in glucuronide-conjugated form, which standard extraction methods miss entirely. In one forensic study, no case samples tested positive until the researchers added an enzymatic hydrolysis step to break apart the glucuronide. After that step, six out of eight samples came back positive, with concentrations ranging from 10 nanograms per milliliter to over 200.⁸

The practical upshot is that even when a lab specifically tests for psilocin, older or less thorough methods could return a false negative if they do not include that hydrolysis step. Modern forensic protocols have largely incorporated this, but the issue illustrates how the metabolic pathway (specifically, heavy glucuronidation) directly influences whether and how the substance can be detected.

Why Individual Responses Vary So Much

Anyone who has talked to multiple people about their psilocybin experiences knows that identical doses can produce very different intensities. Metabolism is one reason. The enzymes involved in clearing psilocin, particularly the UGT family and MAO-A, vary in activity from person to person due to genetics. There is also emerging interest in whether CYP2D6, a liver enzyme with well-known genetic variability, plays a role. Researchers have hypothesized that CYP2D6 metabolizer status could alter the acute psilocybin experience, particularly in people taking monoamine oxidase inhibitors.¹¹ This remains a hypothesis rather than a confirmed finding, but it reflects broader recognition that genetic differences in drug-metabolizing enzymes could explain some of the unpredictability in psilocybin’s effects.

The escalating-dose pharmacokinetic study mentioned earlier also found that some individuals showed an unusually prolonged elimination tail, which the researchers linked to hydrolysis of psilocin-glucuronide back into free psilocin.⁴ In other words, in some people, a portion of the “inactivated” glucuronide breaks back down and re-enters circulation, extending the duration of effects. How much this happens likely depends on individual enzyme profiles and gut bacteria.

The Gut Microbiome and an Open Question

There is growing interest in whether gut bacteria influence psilocybin metabolism. Intestinal microbes produce their own alkaline phosphatases and other enzymes that could theoretically contribute to dephosphorylation. A review of existing evidence found that the composition of the gut microbiome may respond to psychedelic drugs and, conversely, that microbial metabolism could modulate how psychedelics are processed. The evidence is preliminary, mostly based on animal models, and far from the kind of thing anyone can act on. But it suggests that the familiar experience of “same dose, wildly different trips for different people” may partly trace to what is living in their gut, not just their liver enzymes or body weight.

What Happens with Mushrooms Versus Pure Psilocybin

Most clinical research uses synthetic psilocybin in capsule form, but most recreational and traditional use involves whole mushrooms, which contain more than just psilocybin. Psilocybin-producing mushrooms also contain baeocystin, norbaeocystin, and aeruginascin, all of which are structurally related tryptamines with their own phosphate groups. When researchers tested whether alkaline phosphatase shows a preference among these compounds, they found that the enzyme strips the phosphate group from all four at essentially identical rates.¹² Similarly, monoamine oxidase broke all of them down at comparable speeds.

The more interesting finding was about what happens after dephosphorylation. Only the dephosphorylated products of baeocystin and norbaeocystin crossed a blood-brain barrier model to a degree similar to psilocin. The dephosphorylated form of aeruginascin did not cross as effectively.¹² This has implications for the so-called “entourage effect” that mushroom enthusiasts sometimes claim: the idea that whole mushrooms produce a qualitatively different experience than pure psilocybin because of these co-occurring compounds. The metabolic data suggest that at least some of these minor alkaloids do get converted and do reach the brain, though whether they contribute meaningfully to the experience at the concentrations found in mushrooms remains debated.

Synthetic Analogs and How They Differ

The metabolism of psilocybin has also become relevant to the growing interest in synthetic analogs, particularly 4-AcO-DMT (also known as psilacetin or O-acetylpsilocin). This compound is sometimes described as a prodrug for psilocin, analogous to how psilocybin works, but its metabolic pathway is more complex. When researchers incubated 4-AcO-DMT with human liver microsomes, they identified 15 metabolites, including 12 from phase I reactions and 3 from phase II. The biotransformations included hydrolysis (which produces psilocin, as expected), but also hydroxylation, demethylation, oxidation, and glucuronidation of the parent compound itself.¹³ Hydrolysis to psilocin was the most abundant transformation, but the fact that 4-AcO-DMT also undergoes its own direct metabolism means it is not a clean one-to-one psilocybin substitute. Some of those other metabolites could have their own pharmacological activity or toxicity, which is poorly understood.

MAO Inhibitors and a Practical Safety Concern

Because MAO-A is one of the two main enzymes clearing psilocin, anything that inhibits MAO-A will slow psilocin’s elimination and potentially increase both its intensity and duration. Prescription MAO inhibitor antidepressants are the most obvious concern, but MAO inhibition also comes from some herbal supplements (such as Syrian rue, which contains harmine and harmaline) and from the ayahuasca tradition, where MAO inhibitors are deliberately combined with tryptamines.

The pharmacogenomics research mentioned earlier specifically flagged that CYP2D6 metabolizer status could matter more in people combining psilocybin with MAO inhibitors,¹¹ presumably because blocking one clearance route makes the remaining routes more consequential. If MAO-A is inhibited and your UGT enzymes happen to be less active due to genetics, psilocin could accumulate to higher levels and persist longer than expected. Clinical psilocybin trials typically exclude participants on MAO inhibitors for this reason.

Tolerance and Receptor Downregulation

Repeated psilocybin use produces rapid tolerance, with a second dose taken within a day or two producing much weaker effects. This is not a metabolic phenomenon in the traditional sense: your liver does not suddenly get better at clearing psilocin. Instead, the 5-HT2A receptors that psilocin activates become temporarily less responsive, a process called receptor downregulation. Research in mice has confirmed that tolerance to psilocybin develops quickly and that cross-tolerance occurs with other compounds that act on the same receptor.¹⁴ Tolerance typically resolves within one to two weeks as receptors return to baseline sensitivity. The distinction matters because someone who finds a dose “did nothing” after taking psilocybin recently might wrongly assume they need more, when the issue is receptor availability rather than insufficient metabolism to psilocin.

Food, Formulation, and Absorption Variability

The systematic review of psilocybin pharmacokinetics noted considerable variability in how quickly psilocin reaches peak levels, with time-to-peak ranging from 1.8 to 4 hours across studies.² Some of this spread reflects differences in whether participants ate beforehand, the formulation used (capsule, solution, dried mushroom), and individual gastric emptying rates. Food in the stomach generally delays absorption of most oral drugs, and psilocybin appears to be no exception. Clinical trials typically administer psilocybin on an empty or lightly fed stomach to reduce this variability, but the wide range of reported peak times suggests that real-world conditions, including the heavy chitin-containing matrix of a dried mushroom, add meaningful unpredictability to the onset of effects.

The bioavailability estimate of roughly 53% also carries a large standard deviation, meaning some people convert and absorb psilocin much more efficiently than others. Combined with the variable elimination half-life, this paints a picture of a compound whose metabolic handling varies substantially from person to person, even before considering genetic differences in enzyme activity. For clinical programs aiming to deliver precise therapeutic doses, this variability is one of the central pharmacological challenges.

1
PubMed. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance
2
PubMed Central. Pharmacokinetics of Psilocybin: A Systematic Review
3
PubMed. Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants
4
PubMed. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
5
PubMed. Elucidating the Phase I metabolism of psilocin in vitro
6
PubMed Central. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin
7
PubMed Central. Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases
8
Journal of Forensic Sciences. The Detection of Psilocin in Human Urine
9
PubMed. Serotonin 5-HT(2A), 5-HT(2c) and 5-HT(1A) receptor involvement in the acute effects of psilocybin in mice
10
PubMed Central. Molecular insights into the modulation of the 5HT(2A) receptor by serotonin, psilocin, and the G protein subunit Gqα
11
PubMed Central. Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy
12
PubMed. Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms
13
PubMed. Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS
14
PubMed Central. Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT 2A Receptor Agonists in Mice